PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pacira BioSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Share price
+$13.47 (+58.90%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Pacira BioSciences, Inc. grew revenue 5.7% to $746.16M over the twelve months to Jun 30, 2026. Free cash flow was $179.52M, up 53.3% from a year earlier.
Revenue
$746.16M
+5.7% vs. a year earlier
Operating income
$19.87M
TTM Q2 2026
Free cash flow
$179.52M
+53.3% vs. a year earlier
EPS, diluted
$0.35
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.46B
- P/E ratio
- 103.8
- Price to sales
- 1.96
- Price to book
- 2.18
- Dividend yield
- –
- Free cash flow yield
- 12.26%
Fundamentals
- Revenue
- $746.16M
- Net income
- $14.64M
- EPS, diluted
- $0.35
- Free cash flow
- $179.52M
- Book value per share
- $16.67
- Diluted shares
- 40M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$746.16M+5.7% YoY
Gross profit
$591.01M+7.1% YoY
Operating income
$19.87M
Net income
$14.64M
EPS, diluted
$0.35
Free cash flow
$179.52M+53.3% YoY
Reported periodTrailing twelve months